Literature DB >> 9558426

In favor of Coumadin over generic warfarin.

S R Benson1, K Vance-Bryan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9558426     DOI： 10.1093/ajhp/55.7.727

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN： 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  4 in total

1.  Are all warfarin preparations Alike? A comprehensive overview of current data, emerging opinions, and perspectives.

Authors:  N J GiaQuinto
Journal:  J Thromb Thrombolysis       Date:  2000-02       Impact factor: 2.300

2.  Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans.

Authors:  Michael A Fischer; Jerry Avorn
Journal:  Health Serv Res       Date:  2003-08       Impact factor: 3.402

3.  Warfarin in the secondary prevention of thromboembolism in atrial fibrillation: impact of bioavailability on costs and outcomes.

Authors:  Nicole Mittmann; Paul I Oh; Scott E Walker; William R Bartle
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 4.  Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

Authors:  Aaron S Kesselheim; Alexander S Misono; Joy L Lee; Margaret R Stedman; M Alan Brookhart; Niteesh K Choudhry; William H Shrank
Journal:  JAMA       Date:  2008-12-03       Impact factor: 56.272
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.